JW Therapeutics Announces Initiation of Clinical Study of Carteyva® in First-line Treatment in Patients with High-Risk Large B-Cell Lymphoma

SHANGHAI, March 8, 2023 /PRNewswire/ — JW Therapeutics (HKEX: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products, announced the initiation of clinical study of Carteyva® (relmacabtagene…

Leave a Reply

Your email address will not be published. Required fields are marked *